Edition:
United Kingdom

Fate Therapeutics Inc (FATE.OQ)

FATE.OQ on NASDAQ Stock Exchange Global Market

12.84USD
22 Jun 2018
Change (% chg)

-- (--)
Prev Close
$12.84
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
227,112
52-wk High
$14.45
52-wk Low
$2.54

Chart for

About

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from... (more)

Overall

Beta: 1.51
Market Cap(Mil.): $170.63
Shares Outstanding(Mil.): 41.42
Dividend: --
Yield (%): --

Financials

  FATE.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -0.96 -- --
ROI: -72.35 2.00 14.38
ROE: -93.05 3.49 16.08

BRIEF-Fate Therapeutics Files For Mixed Shelf Of Up To $150 Million

* FATE THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING Source text: (https://bit.ly/2KD5gGz) Further company coverage:

04 May 2018

BRIEF-Fate Therapeutics Announces Additional Clinical Data From Phase 1 Stage Of Protect Clinical Trial Of Protmune

* FATE THERAPEUTICS ANNOUNCES ADDITIONAL CLINICAL DATA FROM PHASE 1 STAGE OF PROTECT CLINICAL TRIAL OF PROTMUNE™

19 Mar 2018

BRIEF-Fate Therapeutics Q4 Loss Per Share $0.29​

* FATE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS

05 Mar 2018

Earnings vs. Estimates